KCE Trials is happy to announce that on 19th May 2026, four separate calls for study proposals will open simultaneously.
2026 - KCE Trials comparative effectiveness call
In this call comparative effectiveness studies are funded, comparing two treatment options that are already used in clinical practice for a given indication, but have not yet been sufficiently directly compared. For full information, including inclusion and exclusion, as well as prioritisation criteria, please visit our *website here .
2026 - KCE Trials drug repurposing call
In this call drug repurposing studies investigating a new indication for an off-patent drug are funded. For full information, including inclusion and exclusion, as well as prioritisation criteria, please visit our *website here .
2026 - KCE Trials themed call 'care for addiction'
NEW - KCE Trials is launching a call for study proposals that address clinical research questions in this area. For full details, please visit our *website here .
2026 - KCE Trials themed call on palliative care
NEW - KCE Trials is launching a call for study proposals that address clinical research questions in this area. For full details, please visit our *website here .
*kce.fgov.be and kce.be websites may be blocked by your organization’s firewall. Please ask your local IT support to add our domains to a safe list.
PS: Please note that our sites remain accessible from any “public” internet connection (not filtered by a firewall).
Timelines
The call will open on 19th May 2026. Applications must be submitted via the KCE Trials research management platform (https://kce.smartsimple.ie/).
The deadline for submission is 22nd September 2026, at 13:00.
Information session
An online information session will be organised on Thursday the 4th of June 2026, 10:00-12:00.
For more information, please contact trials”at”kce.fgov.be.
Kind regards
The KCE Trials Team
__________________________________________________________________________
Footnote: No rights can be derived from this prior notice. The final call text and the conditions and criteria set forth therein will prevail.
